Company Encyclopedia
View More
name
Enveric Biosciences
ENVB.US
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Cambridge, Massachusetts.
4.347 T
ENVB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Enveric Biosciences Announces 1-for-12 Reverse Stock Split

    Enveric Biosciences Inc. will execute a 1-for-12 reverse stock split of its common stock, effective October 28, 2025. This action will decrease the number of shares outstanding from approximately 6.2 million to about 518,000. The shares will continue trading on the Nasdaq Capital Market under the symbol "ENVB" on a split-adjusted basis.

    Reuters·
    US
    ENVB
    -6.69%
    Reuters·
    US
    ENVB
    -6.69%

    Enveric Biosciences Secures 23rd U.S. Patent for Novel Neuroplastogenic Compounds Targeting Mental Health Disorders

    Enveric Biosciences has secured its 23rd U.S. patent, U.S. Patent No. 12,428,408, for novel neuroplastogenic compounds aimed at treating mental health disorders. The patent covers a series of fused heterocyclic mescaline derivatives that target serotonin receptors and promote neuroplasticity. This achievement is part of the company's strategy to enhance its intellectual property portfolio and develop next-generation treatments for neuropsychiatric conditions.

    Reuters·
    US
    ENVB
    -6.69%
    Reuters·
    US
    ENVB
    -6.69%

    Pre-market hot trades in US stocks: Enveric Biosciences up 9.99% in pre-market; TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028) up 9.38% in pre-market

    Enveric Biosciences pre-market up 9.99%; TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028) pre-market up 9.38%; Linkage Global pre-market up 148.48%; rYojbaba pre-market up 132.26%; Praxis Precision Medicines pre-market up 125.89%

    Tracking Unusual Activity·
    US
    ENVB
    -6.69%
    US
    TBMCR
    -1.65%
    Tracking Unusual Activity·
    US
    ENVB
    -6.69%
    US
    TBMCR
    -1.65%

    AbbVie's Bretisilocin Hit With Enveric IP Claim

    Enveric Biosciences is challenging AbbVie over its psychedelic candidate bretisilocin, claiming it infringes on their patent (US Patent No. 12,138,276). AbbVie is in the process of acquiring bretisilocin from Gilgamesh for up to $1.2 billion. Enveric's CEO stated they will vigorously defend their IP, and shares rose 20% as investors reacted. The outcome of the patent dispute will impact potential royalties and timelines for the Gilgamesh deal, affecting the development of a new depression therapy.

    GuruFocus·
    US
    ENVB
    -6.69%
    US
    ABBV
    +1.71%
    GuruFocus·
    US
    ENVB
    -6.69%
    US
    ABBV
    +1.71%

    Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie's $1.2B Bretisilocin Acquisition

    Enveric Biosciences ( NASDAQ:ENVB ) recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review ( PGR ) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued U.S.

    Benzinga·
    US
    ENVB
    -6.69%
    Benzinga·
    US
    ENVB
    -6.69%